Cargando…

Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial

BACKGROUND: The optimal way to home-monitor patients with inflammatory bowel disease (IBD) for disease progression or relapse remains to be found. AIM: To determine whether an electronic health (eHealth) screening procedure for disease activity in IBD should be implemented in clinical practice, sche...

Descripción completa

Detalles Bibliográficos
Autores principales: Ankersen, Dorit Vedel, Weimers, Petra, Marker, Dorte, Bennedsen, Mette, Saboori, Sanaz, Paridaens, Kristine, Burisch, Johan, Munkholm, Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824278/
https://www.ncbi.nlm.nih.gov/pubmed/31686770
http://dx.doi.org/10.3748/wjg.v25.i40.6158
_version_ 1783464709187436544
author Ankersen, Dorit Vedel
Weimers, Petra
Marker, Dorte
Bennedsen, Mette
Saboori, Sanaz
Paridaens, Kristine
Burisch, Johan
Munkholm, Pia
author_facet Ankersen, Dorit Vedel
Weimers, Petra
Marker, Dorte
Bennedsen, Mette
Saboori, Sanaz
Paridaens, Kristine
Burisch, Johan
Munkholm, Pia
author_sort Ankersen, Dorit Vedel
collection PubMed
description BACKGROUND: The optimal way to home-monitor patients with inflammatory bowel disease (IBD) for disease progression or relapse remains to be found. AIM: To determine whether an electronic health (eHealth) screening procedure for disease activity in IBD should be implemented in clinical practice, scheduled every third month (3M) or according to patient own decision, on demand (OD). METHODS: Adult IBD patients were consecutively randomized to 1-year open-label eHealth interventions (3M vs OD). Both intervention arms were screening for disease activity, quality of life and fatigue and were measuring medical compliance with the constant care web-application according to the screening interventions OD or 3M. Disease activity was assessed using home measured fecal calprotectin (FC) and a disease activity score. RESULTS: In total, 102 patients were randomized (n = 52/50 3M/OD) at baseline, and 88 patients completed the 1-year study (n = 43 3M; n = 45 OD). No difference in the two screening procedures could be found regarding medical compliance (P = 0.58), fatigue (P = 0.86), quality of life (P = 0.17), mean time spent in remission (P > 0.32), overall FC relapse rates (P = 0.49), FC disease courses (P = 0.61), FC time to a severe relapse (P = 0.69) and remission (P = 0.88) during 1 year. Median (interquartile range) numbers of FC home-monitoring test-kits used per patient were significantly different, 3M: 6.0 (5.0-8.0) and OD: 4.0 (2.0-9.0), P = 0.04. CONCLUSION: The two eHealth screening procedures are equally good in capturing a relapse and bringing about remission. However, the OD group used fewer FC home test-kits per patient. Individualized screening procedures can be recommended for adult IBD patients in clinical web-practice.
format Online
Article
Text
id pubmed-6824278
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-68242782019-11-04 Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial Ankersen, Dorit Vedel Weimers, Petra Marker, Dorte Bennedsen, Mette Saboori, Sanaz Paridaens, Kristine Burisch, Johan Munkholm, Pia World J Gastroenterol Randomized Clinical Trial BACKGROUND: The optimal way to home-monitor patients with inflammatory bowel disease (IBD) for disease progression or relapse remains to be found. AIM: To determine whether an electronic health (eHealth) screening procedure for disease activity in IBD should be implemented in clinical practice, scheduled every third month (3M) or according to patient own decision, on demand (OD). METHODS: Adult IBD patients were consecutively randomized to 1-year open-label eHealth interventions (3M vs OD). Both intervention arms were screening for disease activity, quality of life and fatigue and were measuring medical compliance with the constant care web-application according to the screening interventions OD or 3M. Disease activity was assessed using home measured fecal calprotectin (FC) and a disease activity score. RESULTS: In total, 102 patients were randomized (n = 52/50 3M/OD) at baseline, and 88 patients completed the 1-year study (n = 43 3M; n = 45 OD). No difference in the two screening procedures could be found regarding medical compliance (P = 0.58), fatigue (P = 0.86), quality of life (P = 0.17), mean time spent in remission (P > 0.32), overall FC relapse rates (P = 0.49), FC disease courses (P = 0.61), FC time to a severe relapse (P = 0.69) and remission (P = 0.88) during 1 year. Median (interquartile range) numbers of FC home-monitoring test-kits used per patient were significantly different, 3M: 6.0 (5.0-8.0) and OD: 4.0 (2.0-9.0), P = 0.04. CONCLUSION: The two eHealth screening procedures are equally good in capturing a relapse and bringing about remission. However, the OD group used fewer FC home test-kits per patient. Individualized screening procedures can be recommended for adult IBD patients in clinical web-practice. Baishideng Publishing Group Inc 2019-10-28 2019-10-28 /pmc/articles/PMC6824278/ /pubmed/31686770 http://dx.doi.org/10.3748/wjg.v25.i40.6158 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Randomized Clinical Trial
Ankersen, Dorit Vedel
Weimers, Petra
Marker, Dorte
Bennedsen, Mette
Saboori, Sanaz
Paridaens, Kristine
Burisch, Johan
Munkholm, Pia
Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial
title Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial
title_full Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial
title_fullStr Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial
title_full_unstemmed Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial
title_short Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial
title_sort individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: a randomized-clinical trial
topic Randomized Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824278/
https://www.ncbi.nlm.nih.gov/pubmed/31686770
http://dx.doi.org/10.3748/wjg.v25.i40.6158
work_keys_str_mv AT ankersendoritvedel individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial
AT weimerspetra individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial
AT markerdorte individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial
AT bennedsenmette individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial
AT saboorisanaz individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial
AT paridaenskristine individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial
AT burischjohan individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial
AT munkholmpia individualizedhomemonitoringofdiseaseactivityinadultpatientswithinflammatoryboweldiseasecanberecommendedinclinicalpracticearandomizedclinicaltrial